Introduction
Autocrine transforming growth factor a (TGFa) is an important determinant of abnormal growth in malignant progression. Both TGFa overexpression and aberrant control of its cognate receptor, the epidermal growth factor receptor (EGFr) have been associated with malignant progression (Derynck et al., 1987; Ziober et al., 1993; Khazaie et al., 1993) . The evidence for an important role in the deregulated growth of colon cancer in vitro and in vivo is particularly strong. For example, immunoreactive TGFa has been frequently detected in colon cancer (Tanaka et al., 1991) and its expression is higher in tumors than in normal mucosa (Liu et al., 1990) . TGFa transgenic mice showed hyperplasia of the colon (Sandgren et al., 1990; Vassar and Fuchs, 1991) and overexpression of a TGFa cDNA signi®cantly stimulated malignant progression in an early stage model of colon carcinoma (Ziober et al., 1993) . In contrast, abrogation of TGFa expression by stable expression of an antisense TGFa cDNA reversed the malignant behavior of highly progressed human colon carcinoma cells (Howell et al., 1995 (Howell et al., , 1998 .
While autocrine TGFa appears to have a signi®cant role in progression, the mechanism by which it confers a growth advantage to tumor cells and how the expression of this autocrine activity is controlled are still largely unclear. These are particularly important issues since it is now clear that normal cells also express autocrine TGFa (Bates et al., 1990; Coey et al., 1992; Pittelkow et al., 1993) . Previously, comparison of the mRNA expression of autocrine TGFa in highly progressed late stage versus early stage relatively non-progressed human colon carcinoma cells showed that TGFa was aberrantly up-regulated in growtharrested progressed cells. In contrast, early stage colon carcinoma cells, like normal cells, showed decreased TGFa expression in quiescence (Mulder, 1991) . The TGFa regulation in both cell types was under transcriptional controls which were associated with speci®c changes in nuclear DNA binding proteins which bind to the TGFa autoregulatory region of the promoter (Howell et al., 1998) . These results suggested that autocrine TGFa acts in the process of growth initiation or re-entry into the cell cycle, but it is still not clear how autocrine TGFa expression is controlled or how it functions during cell cycle re-entry from the growth-arrested state. This work is directed at understanding these controls in an early malignant, colon carcinoma cell line FET with low tumorigenicity (Wu et al., 1992) . This model is of particular interest because it requires exogenous activation of the insulin-like growth factor-I receptor (IGF-IR) for reentry into the cell cycle. Therefore, if autocrine TGFa is necessary for cell cycle re-entry in these cells, it would be likely that autocrine TGFa and hence the EGFr signaling pathway would be interacting with the IGF-IR pathway to induce DNA synthesis in a cooperative manner.
The IGF-IR, which is responsible for the mitogenic activity of insulin, insulin growth factor I (IGF-I) and IGF-II (Stewart et al., 1990) , is a preformed heterotetramer composed of two extracellular a-and two transmembrane b-subunits (Schmid, 1995; Blakesley et al., 1997) . Upon ligand binding, the intracellular tyrosine kinase subdomain located in the b-subunit becomes activated, leading to receptor phosphorylation and signal transduction. This receptor has been shown to be necessary for the mitogenic activity of EGFr (Coppola et al., 1994) and BALB/c3T3 cells overexpressing both IGF-I and IGF-IR grow in serum-free medium without any exogenous growth factors (Pietrzkowski et al., 1992) . Based on these observations, it has been hypothesized that IGF-IR is downstream of EGFr in the mitogenic process and that once IGF-IR is activated, EGFr activation becomes unnecessary for the S phase entry (Werner and LeRoith, 1996) . However, the IGF-IR dependency of growth factor dependent colon carcinoma cells for re-entry into the cell cycle suggested that IGF-IR activation preceded EGFr activation and that IGF-IR was actually required for TGFa induction. Given that much of the work associated with the development of the concept that IGF-IR activation was downstream of EGFr activation was performed with cells overexpressing IGF-IR, we decided to test the hypothesis that EGFr activation could be downstream of IGF-IR activation in a cell line where neither component is ectopically expressed.
The FET colon carcinoma cell line was derived from an early stage human colon cancer and has been adapted to grow in a completely chemically de®ned serum-free medium (Brattain et al., 1981 (Brattain et al., , 1984 Chantret et al., 1988; Schlechte et al., 1990; Jiang et al., 1998) . This has allowed for the determination of speci®c exogenous growth factor requirements for FET cells which include transferrin and insulin for continuous growth in serumfree medium (Brattain et al., 1994) . The lack of an absolute requirement for exogenous growth factor activation of the EGFr indicated that either autocrine TGFa activation of the EGFr was sucient for FET DNA synthesis or that activation of IGF-IR substituted for EGFr function in these cells. To test these possibilities we have examined the control of autocrine TGFa expression as well as expression and activation of EGFr and their relationship to activation of the IGF-IR during the establishment of growth arrest and re-entry into the cell cycle. Here we report that IGF-IR activation precedes and is a pre-requisite for the subsequent activation of the autocrine TGFa pathway during S phase re-entry in FET cells. During growth arrest established by exogenous growth factor deprivation, both TGFa and EGFr are down-regulated at the transcriptional level and therefore, EGFr activation is also down-regulated. Total IGF-IR levels are not downregulated, but IGF-IR is not activated in the absence of exogenous ligand.
In order for FET cells to re-enter the cell cycle, both activation of the IGF-IR by exogenous ligand and upregulation of the autocrine TGFa pathway are required. Activation of the IGF-IR results in both increased autocrine TGFa and EGFr expression and EGFr activation which becomes maximal within 4 h of IGF-IR activation. The binding activity of the previously identi®ed nuclear DNA-binding proteins which bind to a 25 bp TGFa/EGF response element within the TGFa promoter (Howell et al., 1998a) was similarly enhanced following IGF-IR activation as determined by gel shift analysis. Thus, we have shown, for the ®rst time, that the autocrine TGFa pathway can be controlled downstream of the IGF-IR pathway and that the activation of autocrine TGFa is necessary for maximal DNA synthesis in early stage colon carcinoma cells dependent upon exogenous growth factors for optimal DNA synthesis. Thus, we have shown that autocrine TGFa provides these malignant cells with a growth advantage over normal cells in that only one exogenous mitogenic factor is required for re-entry into the cell cycle from a growth-arrested state. Moreover, we have shown that autocrine TGFa mediated activation of the EGFr can occur downstream rather than upstream of IGF-IR activation.
Results

Repression of TGFa autocrine activity during the induction of growth arrest
Growth arrest was induced by nutrient and growth factor deprivation for 6 days during which DNA synthesis was monitored by [ 3 H]-thymidine incorporation assays. The acquisition of a steady, low basal level of [ 3 H]-thymidine incorporation was operationally de®ned as growth arrest in this model system ( Figure  1a ). Flow-cytometry assays showed *85% of the cells were arrested in G 0 /G 1 at this time (data not shown).
A TGFa speci®c RNase protection assay was utilized to monitor TGFa expression at the mRNA level during the establishment of growth arrest as described in However, repression of TGFa expression in growtharrested FET cells does not necessarily mean that the EGFr activation and the associated signal transduction pathways would also be reduced. For example, other EGF-like ligands such as amphiregulin might activate the EGFr. Consequently, EGFr expression and activation in growth arrested FET cells were measured by RNase protection assay and immunoblotting. FET cells in late exponential phase showed a relatively high level of EGFr mRNA and protein, while EGFr mRNA and protein expression in growth-arrested FET cells was repressed (Figure 2a,b) . The level of EGFr protein expression was virtually undetectable in growtharrested FET cells. To measure the level of the EGFr activation, we used a monoclonal antibody which was developed using ligand-activated EGFr protein as antigen. This antibody has been shown to recognize only activated EGFr protein (Campos-Gonzalez and Glenney, 1991a,b; Jiang et al., 1998; Yang et al., 1999) . EGFr activation was undetectable in growth-arrested FET cells while exponential phase cells exhibited high levels of activation (Figure 2b ). Thus, both the expression of autocrine TGFa and the activation of its autocrine signal transduction pathway were repressed in growth-arrested FET cells as re¯ected by a lack of EGFr expression and activation.
Expression of IGF-IR in growth-arrested FET cells
Since the activation of IGF-IR by exogenous ligand is required for proliferation of FET cells, we determined the level of expression and activation of this receptor during the establishment of growth arrest. While we detected a signi®cant decrease in TGFa and EGFR at the mRNA level, IGF-IR mRNA levels remained high at growth arrest (Figure 3a) . In addition, growtharrested FET cells expressed IGF-IR protein at a level comparable with exponential phase FET cells ( Figure  3b) . However, the level of IGF-IR activation was decreased in quiescent cells compared to exponentially growing FET cells (Figure 3b ). Therefore, growth arrest leads to repression of the level and expression of autocrine TGFa pathway components and hence EGFr activation, while only IGF-IR activation was repressed. The maintenance of a high level of IGF-IR protein in growth-arrested cells suggested that this receptor was immediately available to be activated by exogenous ligand. On the other hand, if EGFr were to play an important role in cell cycle re-entry, it would ®rst (Figure 4a ). In contrast, treatment of growth-arrested FET cells with SM medium alone induced only a small fraction of this DNA synthesis (20%), indicating that IGF-IR activation was required for optimal re-entry of growth-arrested FET cells into the cell cycle ( Figure 4a ). Transferrin alone is non-mitogenic (Huebers and Finch, 1987) and its exclusion has no eect on insulin induced DNA synthesis (data not shown). To eliminate the possibility that the DNA synthesis was mediated by insulin receptor, we compared the concentration dependence of insulin, IGF-I and IGF-II for optimal DNA synthesis. Insulin activates its own receptor at low concentration (10 ng/ ml) while higher concentrations of insulin are required for IGF-IR activation (Stewart et al., 1990) . Insulin showed no eect on DNA synthesis at 10 ng/ml and its maximal mitogenic eect required a concentration of 5 mg/ml (Figure 4b ). In contrast, optimal concentrations for IGF-I and IGF-II were 20 ng/ml and 50 ng/ml, respectively ( Figure 4c ). Therefore, we conclude that it is IGF-IR rather than insulin receptor which is mediating the S phase entry.
We then determined the role of the autocrine TGFa pathway in DNA synthesis by treating cells with TGFa neutralizing antibody during release from growth arrest in the presence of insulin. The TI-induced DNA synthesis was inhibited by *65% in the presence of 30 mg/ml TGFa neutralizing antibody (Figure 4d ). In a separate experiment, 20 mg/ml TGFa neutralizing antibody inhibited insulin induced DNA synthesis by *50% (data not shown). Therefore, autocrine TGFa was necessary to support the re-entry into the cell cycle following IGF-IR activation. These results implied that IGF-IR activation stimulated autocrine TGFa activity for maximal DNA synthesis to occur. Therefore, we determined the kinetics of induction of TGFa expression and EGFr activation relative to the time after IGF-IR ligand treatment of growth-arrested FET cells.
Stimulation of TGFa expression and EGFr activation precedes induction of DNA synthesis
If autocrine TGFa was required for re-entry of the cells into the cell cycle, induction of TGFa expression and activation of the EGFr should occur prior to DNA synthesis. Signi®cant induction of DNA synthesis in growth-arrested cells began at 12 h following release Figure 4a , while stimulation of TGFa expression at the mRNA level was already apparent by 1 h and maximal at 4 h ( Figure 5 ). The TI medium stimulated TGFa expression by *threefold. Consistent with its inability to fully stimulate DNA synthesis, SM medium gave rise to a lower level of TGFa expression ( Figure 5 ). The expression of EGFr was monitored concurrently with TGFa as a function of time after release from growth arrest following insulin treatment or treatment with SM medium alone. Signi®cant induction of the EGFr mRNA ( Figure 5a ) and protein ( Figure 5b ) was observed by 1 h following the addition of insulin. The SM medium was a much weaker inducer of EGFr protein expression than the insulin containing medium. Signi®cantly, EGFr activation was markedly stimulated by TI but only very weakly following SM treatment (Figure 5c ). Moreover, addition of the selective EGFr kinase inhibitor AG1478 (Levitzki and Gazit, 1995) along with insulin markedly suppressed the activated IGF-IR-mediated EGFr activation in a dose-dependent manner (Figure 5d ). The extent of EGFr activation was signi®cantly inhibited by 0.5 mM AG1478 and completely abolished at 5 mM. The addition of AG1478 did not aect the total level of EGFr protein expression (data not shown). Moreover, AG1478, like EGFr neutralizing antibody, dose-dependently inhibits TI-stimulated mitogenesis in FET cells (data not shown). Release of growth-arrested FET cells with SM medium supplemented with transferrin and IGF-I also induced EGFr activation in a similar manner (data not shown). Therefore, EGFr activation induced by TI preceded DNA synthesis in growth-arrested FET cells and this induction was mediated by autocrine TGFa.
In previous studies we have shown that stimulation of autocrine TGFa expression in colon carcinoma cells is associated with increased TGFa promoter activity and increased binding of DNA-binding proteins to a 25 bp TGFa/EGF-responsive cis-element within the TGFa promoter (Howell et al., 1998) . Following TI treatment of quiescent FET cells, the binding of these same DNAbinding proteins was similarly induced as analysed by gel shift assay (Figure 6 ). These included 3 major low mobility shift complexes (bands 1-3) and a minor high mobility shift component (band 5). Another high mobility shift complex designated band 4 is not growth factor regulated as previously described (Howell et al., 1998) . The protein binding to the TGFa/EGF response element is highly induced at 1 h following TI treatment and maximal at 4 h. While this binding occurs simultaneously with the stimulation of autocrine TGFa expression and so is attributable to TGFa autoinduction of binding (and so promoter activity) we cannot rule out the possibility that some binding may be stimulated by the direct action of insulin acting through the IGF-IR.
EGFr activation is downstream of IGF-IR activation
IGF-IR protein levels remained constant at 5 and 15 min after FET cells were released from growth arrest by Taken together, these results indicated that TGFa autocrine activity was up-regulated by IGF-IR activation. Reactivation of this autocrine activity in growtharrested FET cells plays an important role in re-entry into the cell cycle. This also implies that the downregulation of TGFa autocrine activity might be the explanation for the dependence on exogenous insulin for re-entry into the cell cycle. Interestingly, highly progressed HCT116 human colon carcinoma cells upregulate their TGFa autocrine activity at growth arrest (Howell et al., 1998) . The growth arrested HCT116 cells are also insulin independent for re-entry into the cell cycle (Mulder and Brattain, 1989) . This led us to hypothesize that the inappropriate expression of autocrine TGFa in growth arrest is the driving force behind the growth factor independent phenotype exhibited by HCT116 cells. To test this hypothesis, we stably transfected a TGFa expression vector into FET cells so that FET cells would constitutively express TGFa, thus preventing the down-regulation of this autocrine activity in growth arrest.
Constitutive TGFa expression led to insulin/IGF-I independence FET6, a typical limiting dilution clone of FET cells, was chosen for this study. The human TGFa cDNA was subcloned into the tetracycline repressible mamma- lian cell expression system (Gossen and Bujard, 1992; Jiang et al., 1998; Yang et al., 2000) . FET6 cells were transfected by electroporation and Neo resistant clones were expanded and tested for expression of the transfected TGFa cDNA (Jiang et al., 1998) . TGFa expression in a typical clone (designated FET-aS26) is shown in Figure 8a . Expression could be reversed by tetracycline treatment (0.1 mg/ml) for 24 h (Figure 8a ). To test whether the high level of TGFa expression in the transfected cells resulted in higher EGFr signal transduction in growth arrest, we compared the EGFr activation levels in the Neo control and in the TGFa sense transfectant. The TGFa transfectant, as expected, showed signi®cantly higher levels of EGFr activation than the Neo control in the quiescent state (Figure 8b ). This EGFr activation could be reversed by treating the TGFa-transfected cells with 0.1 mg/ml tetracycline, suggesting that the high level of constitutive EGFr activation was due to the continued expression of TGFa. Further, nuclear protein binding activity to the 25 bp TGFa/EGF response element in the TGFa promoter was also induced in a reversible manner (Figure 8c ) as was the expression of endogenous TGFa mRNA (Figure 8a ). The expression of the transfected TGFa cDNA in the stable transfectant also led to high level of secreted functional TGFa protein as con®rmed by a commercial TGFa Elisa assay (Oncogene Science; data not shown). We next investigated whether this inappropriate expression of TGFa conferred growth factor indepen- They were harvested at the indicated times and nuclear extracts were prepared. Gel shift analyses were performed as described in Materials and methods. 1 mg poly dI : dC was also added into the binding mixture to prevent non-speci®c binding. Competition studies with cold oligonucleotide were performed to con®rm speci®city of binding. Several putative insulin regulated bands were observed. These included three major low-mobility-shift complexes, labeled as bands 1, 2, and 3 and a minor highmobility-shift band, band 5. Another high-mobility-shift complex, band 4, seems not to be regulated following TI treatment dence to FET-as26 cells. Cells were plated in SM medium (no exogenous growth factors) at a density of 50 000 cells per well and [ 3 H]-thymidine incorporation assays were then performed at the indicated times to monitor their growth activity. FET6-Neo cells showed no appreciable growth (Figure 9a ), but the FET-as26 cells had acquired the ability to grow in the SM medium, and this activated IGF-IR independent cell growth was reversed by treating the cells with 0.1 mg/ml tetracycline (Figure 9a ). Growth arrested FET-as26 cells also acquired the ability to reenter the cell cycle independent of exogenous insulin. Nutrient replenishment alone (SM; Figure 9b ) was sucient to release the cells from quiescence as monitored by mitogenesis assay. However, growth arrested FET6-Neo cells, like the parental FET cells, required both nutrients and IGF-IR activation for release into the cell cycle (TI; Figure 9b ). Again, treatment of FET-aS26 cells with tetracycline (0.1 mg/ml) reversed the activated IGF-IR independent phenotype (Figure 9b ).
Discussion
The autocrine hypothesis was introduced to account for the growth advantage of malignant cells over their normal counterparts. TGFa was one of the ®rst growth factors described to behave in this manner (DeLarco and Todaro, 1978) . Our understanding of this polypeptide growth factor and its mechanism of signal transduction have seen a precipitous expansion over the last decade. However, despite these advances, the mechanism underlying autocrine growth factor action remains largely unknown. This is the ®rst report that the expression of both TGFa and EGFr is dependent upon IGF-IR activation. Removal of IGF-IR ligand from tissue culture medium led to down-regulation of TGFa and EGFr expression and, as a result, elimination of EGFr activation. Consistent with the down-regulation of TGFa expression, previously identi®ed nuclear protein binding activity to the EGF/TGFa cis-element controlling TGFa expression in the TGFa promoter (Howell et al., 1998) was absent in growth-arrested FET cells. This result provides evidence to support the previous observation that this cis-element appears to be required for maintaining the basal promoter activity in addition to EGF/TGFa responsiveness of the TGFa promoter (Howell et al., 1998) .
The TGFa autocrine system in FET cells must be reactivated for the majority of the cells to re-enter the cell cycle. The induction of autocrine TGFa mediated EGFr activation in early G 1 is an essential event for DNA synthesis as shown by TGFa or EGFr neutralizing antibody or AG1478 blockade of DNA synthesis as well as EGFr activation. Some reactivation of TGFa expression occurs as a result of nutrient replenishment to growth arrested FET cells. While this might be explained by the weak induction of IGF-IR activation by SM medium, this might also re¯ect the recognized role of glucose conversion to glucosamine through the L-glutamine: D-fructose-6-phosphate aminotransferase enzyme in the stimulation of TGFa expression (McClain et al., 1992; Roos et al., 1996; Sayeski and Kudlow, 1996) . The SM medium would provide fresh glucose to growth-arrested FET cells. However, in order to obtain substantial TGFa autocrine reactivation and re-entry into the cell cycle, exogenous ligand activation of the IGF-IR must occur as evidenced by the fact that insulin containing medium is much more eective in inducing both DNA synthesis, TGFa and EGFr expression and EGFr activation than SM medium. Our results show, for the ®rst time, that autocrine TGFa function lies downstream of IGF-IR activation during cell-cycle reentry in the growth factor dependent FET cell line. The IGF-IR axis therefore appears to be a competence mechanism for autocrine TGFa. However, the exact mechanism by which IGF-IR stimulates TGFa expression and EGFr activation is unclear. One possibility is that stimulation with TI induces TGFa transcription as evidenced by the increased protein binding to the 25 bp cis-element within the TGFa promoter which mediates TGFa autoregulation of its own transcription (Howell et al., 1998) . The subsequent increase in TGFa expression would then result in EGFr activation and expression. The TI may induce increased TGFa promoter activity through IGF-IR signaling via the MAP kinase or PI3 kinase pathways.
Constitutive expression of TGFa mRNA in FET cells abrogated the requirement for exogenous IGF-IR ligands to enter the cell cycle. These cells constitutively express TGFa in growth arrest and replenishment with SM alone was sucient for these cells to re-enter the cell cycle after the establishment of quiescence. These cells showed constitutive EGFr activation and increased TGFa production as evidenced by the level of endogenous TGFa mRNA expression and the constitutive binding of the DNAbinding proteins to the 25 bp TGFa/EGF response element in the quiescent cells. The addition of tetracycline to these cells repressed the constitutive TGFa mRNA expression and led to reversion to the activated IGF-IR dependent phenotype. The FET cells constitutively expressing TGFa mRNA show a growth factor independent phenotype characteristic of the Cells were again starved in the presence and absence of tetracycline highly progressed, growth factor independent HCT116 colon carcinoma cell line. These cells maintain endogenous TGFa expression during the establishment of quiescence and these quiescent cells do not require any exogenous growth factors to re-enter the cell cycle (Mulder and Brattain, 1989) . However, stable TGFa antisense RNA expression in HCT116 cells leads to repression of autocrine TGFa and the requirement of both nutrients and growth factors for release from growth arrest (Howell et al., 1995 (Howell et al., , 1998 . Interestingly, one of the required growth factors is insulin for IGF-IR activation. Therefore, this mechanism does not appear to be unique to the FET cell line. Therefore, IGF-IR ligands may be competence factors for S phase re-entry in growth factor dependent phenotype human colon carcinoma cells expressing autocrine TGFa loops. Taken together, these results indicate that the ability to maintain autocrine TGFa expression in the quiescent state along with the subsequent maintenance of EGFr activation contributes to the growth factor independent phenotype and ultimately leads to the development of a more progressed phenotype. However, wild-type FET cells, which do not maintain high levels of TGFa expression and constitutive EGFr activation in quiescence, require both nutrients and growth factors to re-enter the cell cycle. This exogenous growth factor is required speci®cally to activate the IGF-IR receptor, which then induces expression of the autocrine TGFa system.
Materials and methods
Cell culture
The FET cell line was developed from an early stage human colon cancer and has been extensively characterized (Brattain et al., 1981 (Brattain et al., , 1994 Chantret et al., 1988; Schlechte et al., 1990) . FET6 is a typical limiting dilution clone of FET cells. Both the parental FET and FET6 cells have been continuously maintained in a chemically de®ned serum-free medium as previously described (Boyd et al., 1988; Mulder and Brattain, 1989) . The basis of this medium consists of McCoy's 5A medium (Gibco BRL) supplemented with amino acids, pyruvate, antibiotics, referred to as Supplemental McCoy's medium. The growth factors, insulin (20 mg/ml, Sigma) and transferrin (4 mg/ml, Sigma) are added to this. Working cultures were maintained at 378C in the presence of 5% CO 2 . Cells were routinely subcultured with 0.25% trypsin in Joklik's medium containing 0.1% EDTA. IGF-I and IGF-II were purchased from R&D Systems. The selective EGFr kinase inhibitor AG1478 (Levitzki and Gazit, 1995) was purchased from Calbiochem. The growth factor free Supplemental McCoy's medium was designated SM. The SM medium containing transferrin and insulin was designated as TI medium.
Gel shift analysis
Cells were harvested at the indicated times. FET cells were lysed with a type B pestle in homogenization buer (10 mM HEPES, 1.5 mM MgCl 2 , 10 mM KCl, pH 7.6) as described by Dignam et al. (1983) . Following centrifugation, nuclear proteins were extracted from the partially puri®ed nuclei by addition of 3 M KCl to a ®nal concentration of 0.6 M and ammonium sulfate precipitated as described by Gorski et al. (1986) . Following dialysis against 25 mM HEPES, pH 7.6, containing 0.1 mM EDTA, 40 mM KCl, 10% glycerol, and 1 mM dithiothreitol, nuclear extracts were concentrated to 5 to 10 mg/ml with Aquacide I (Calbiochem), aliquoted, snapfrozen in liquid N 2 , and stored at 7808C.
High speci®c-activity double-stranded oligonucleotide labeled with 32 P-ATP by T4 polynucleotide kinase was incubated with nuclear extract in a ®nal volume of 20 ml (Gorski et al., 1986) . Following incubation on ice, the reaction mix was loaded onto a 4% polyacrylamide gel in 25 mM Tris-25mM boric acid buer containing 0.5 mM EDTA and run at 150 to 250 V at 48C (Scheidereit et al., 1987) . Poly-dI : dC (1 mg per reaction) was also added into the binding mixture to prevent non-speci®c binding. Nuclear extracts were run against synthesized, double-stranded oligonucleotide comprising the 25-bp TGFa autoregulatory element (7225 to 7201 of the TGFa promoter, relative to the translation start codon: Howell et al., 1998) . Competition studies with cold oligonucleotide were performed to con®rm speci®city of binding.
Mitogenesis assay
This protocol was carried out as previously described with some minor modi®cations (Mulder and Brattain, 1989) . Brie¯y, con¯uent cells were changed into Supplemental McCoy's (SM medium) and growth-arrested by growth factor and nutrient deprivation for 6 days. Subsequently, cells were released from quiescence by providing fresh nutrients alone (changing the cultures with SM medium) or nutrients plus the growth factors transferrin and insulin (TI medium). Cells were pulsed for 1 h with 25 mCi 
RNase protection assay
High speci®c activity human TGFa and g-actin riboprobes were synthesized in vitro from a 306 bp 5'-fragment and a 145 bp 5'-fragment of their respective cDNA's cloned into the pGEM3Z (7) vector (Promega) in the presence of [ 32 P]-UTP (3000 Ci/mM, NEN) as previously described (Howell et al., 1995) . The EGFr riboprobe was synthesized from the 404 bp EcoRI: BamHI 5'-fragment of its cDNA subcloned into the pGEM3Z (7) vector. The IGF-IR riboprobe was synthesized from the 249 bp BspEI: XhoI restriction fragment of IGF-IR cDNA subcloned into the pBSK vector. Following DNaseI digestion of the template, the riboprobes were isolated with a NACS-52 column (Gibco BRL).
Total cellular RNA was isolated in 5 M guanidine isothiocyanate and puri®ed using a cesium tri¯uoroacetate gradient (Chirgwin et al., 1979) . Total RNA (40 mg) was hybridized with the riboprobes overnight. After RNase digestion of excess riboprobe, protected fragments were resolved on a 6% urea-polyacrylamide sequencing gel followed by autoradiography. The actin probe was used to normalize the loading of the gels (Enoch et al., 1986) .
Stable transfection
Human TGFa cDNA was subcloned into the tetracyclinecontrolled mammalian cell expression system (Gossen and Bujard, 1992) ; Jiang et al., 1998) . Con¯uent FET6 cells, a typical limiting dilution clone of FET, were harvested by trypsinization and 2.0610 7 cells were then transferred to a 0.4 cm electrogap cuvette (BioRad) with the tetracyclinecontrolled TGFa expression vectors. After electroporation at 250 volts and 960 mF in a BioRad gene pulser, the cells were plated at a 1 : 20 to 1 : 30 dilution and changed to medium containing 600 mg/ml Geneticin (Neo: G418, Gibco BRL) at 48 h later. Neo resistant clones were expanded and tested for the expression of the transfected TGFa cDNA using the RNase protection assay.
Immunoblotting and immunoprecipitation
EGFr antibody and activated-EGFr speci®c antibodies (Transduction Laboratories) were used to measure total EGFr protein and EGFr activation, respectively. FET cells were lysed in lysis buer (50 mM Tris-HCl, 150 mM NaCl, 0.5% NP-40, 50 mM NaF, 1 mM NaVO3, 1 mM PMSF and 25 mg/ml trypsin inhibitor, pH 7.4) at the indicated times in speci®c experiments. Protein concentrations were determined by microassay using bicinchoninic reagent (Pierce). Cell lysate (75 mg for EGFr antibody and 150 mg for activated-EGFr antibody) was resolved by 7.5% SDS ± PAGE and blotted onto nitrocellulose membranes (Amersham). After incubation for 2 h at room temperature with EGFr antibody (1 mg/ml) or activated EGFr antibody (2 mg/ml) in TTBS buer (20 mM Tris-HCl, 500 mM NaCl and 0.05% Tween-20) containing 5% non-fat dry milk, the blot was washed three times with TTBS and incubated with horseradish peroxidase conjugated secondary antibody (1 mg/ml) in TTBS-5% dry milk for 1 h at room temperature. Following three TTBS washes, the blot was developed with the ECL system according to the manufacturer's protocol (Amersham).
A polyclonal antibody against the IGF-IR b-subunit (Santa Cruz) was used in immunoblotting to measure the IGF-IR protein level. The procedure was the same as the EGFr immunoblotting except that 10% SDS ± PAGE was used. To measure IGF-IR phosphorylation, cell lysates were incubated with 2 mg anti-phosphotyrosine (p-Tyr) antibody (PY20; Transduction Laboratories) overnight. The antibodyantigen complex was then precipitated with protein-A agarose and the pellet was washed three times. The p-Tyr containing protein was eluted with elution buer (50 mM Tris-HCl, 1% SDS, 10% glycerol, 0.02% bromophenol blue, pH 6.8) and resolved by 10% PAGE followed by IGF-IR immunoblotting as described above.
